Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bioasis Technologies Inc. V.BTI

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and the xB3™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need. The in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.


TSXV:BTI - Post by User

Post by Boomskidon Jan 18, 2023 9:25am
111 Views
Post# 35230217

The Cost of Selling Something

The Cost of Selling Something The question I've always had is how much does it cost to sell something? 

Bioasis has entered a number of material transfer agreements (MTAs) where there was no money involved. Although I'm not advocating giving away xB3-001 or anything else, it is a starting point in the intellectual game of evaluation.

What is the lowest upfront payment and subsequent milestones at which it's a no-brainer for someone to buy xB3-001 or something else? 

How hard can that be? Was that actually done with Ellipses? Why did Bioasis end up selling everything for almost nothing anyway, with over 75% of Biodexa going into private hands?

It's a failure of such astonishing magnitude that it ought to be investigated. 

I don't believe this deal would have been done if xB3 had failed. If xB3 hasn't failed then xB3 is the target of the acquisition. xB3 is what the buyers want.

I have no doubt now that Bioasis was run into the ground. But was it through incompetence or neglect, or was it purposeful? 

We'll know the answer when we see where the big xB3 opportunities end up, but of course it'll be too late then. 

jd
<< Previous
Bullboard Posts
Next >>